HALOZYME THERAPEUTICS, INC. - Common Stock (HALO)

Historical Holders from Q1 2014 to Q3 2025

Symbol
HALO on Nasdaq
Type / Class
Equity / Common Stock
Shares outstanding
123,650,000
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
119,195,098
Holdings value
$8,740,425,209
% of all portfolios
0.009%
Number of holders
592
Number of buys
291
Number of sells
-286
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 10.2% -22.3% $656,091,846 -$183,727,565 12,612,300 -21.9% BlackRock, Inc. 30 Jun 2025
STATE STREET CORP 4.9% $358,640,665 6,053,007 STATE STREET CORPORATION 31 Mar 2025

Institutional Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 119,195,098 $8,740,425,209 +$218,977,631 $73.34 592
2025 Q2 116,352,424 $6,053,937,391 -$203,145,554 $52.02 541
2025 Q1 120,489,904 $7,687,315,257 -$91,368,957 $63.81 543
2024 Q4 122,458,776 $5,856,815,335 -$193,231,691 $47.81 500
2024 Q3 125,205,134 $7,161,621,740 +$188,148,727 $57.24 503
2024 Q2 122,186,529 $6,397,611,292 -$49,238,862 $52.36 449
2024 Q1 123,583,310 $5,026,636,534 -$29,500,183 $40.68 409
2023 Q4 124,680,353 $4,614,991,205 +$45,612,024 $36.96 409
2023 Q3 123,213,224 $4,707,973,255 -$3,726,561 $38.2 389
2023 Q2 123,025,101 $4,439,170,134 -$50,628,033 $36.07 368
2023 Q1 124,051,427 $4,736,116,144 -$286,882,621 $38.19 381
2022 Q4 129,468,465 $7,364,542,615 -$117,989,602 $56.9 414
2022 Q3 131,997,507 $5,220,452,246 +$129,179,246 $39.54 345
2022 Q2 128,322,139 $5,647,663,757 +$24,849,414 $44 359
2022 Q1 128,337,653 $5,115,592,058 -$42,336,732 $39.88 298
2021 Q4 129,389,920 $5,202,313,554 -$77,902,534 $40.21 314
2021 Q3 130,048,093 $5,289,784,296 +$44,615,821 $40.68 316
2021 Q2 129,727,357 $5,890,257,760 -$85,620,767 $45.41 309
2021 Q1 132,146,550 $5,510,245,951 -$141,977,795 $41.69 329
2020 Q4 136,300,724 $5,821,984,170 +$126,547,922 $42.71 335
2020 Q3 133,950,846 $3,522,042,268 -$34,152,841 $26.28 262
2020 Q2 135,245,376 $3,623,665,867 +$159,039,078 $26.81 256
2020 Q1 130,660,067 $2,348,012,984 +$56,330,665 $17.99 205
2019 Q4 127,472,754 $2,260,145,336 +$7,244,846 $17.73 218
2019 Q3 126,453,885 $1,961,243,729 +$54,882,291 $15.51 206
2019 Q2 122,604,908 $2,104,656,029 +$207,889,231 $17.18 199
2019 Q1 121,175,132 $1,950,961,461 +$3,424,262 $16.1 198
2018 Q4 120,370,571 $1,760,962,328 -$41,616,936 $14.63 186
2018 Q3 122,639,238 $2,228,291,177 +$6,384,296 $18.17 191
2018 Q2 122,789,328 $2,071,554,889 -$21,158,536 $16.87 193
2018 Q1 123,600,167 $2,421,268,422 +$15,633,634 $19.59 208
2017 Q4 122,499,248 $2,482,081,024 +$20,859,736 $20.26 196
2017 Q3 121,459,215 $2,109,824,400 -$3,854,105 $17.37 164
2017 Q2 121,956,653 $1,561,931,486 +$88,012,978 $12.82 164
2017 Q1 115,142,534 $1,492,238,870 +$198,524,663 $12.96 155
2016 Q4 110,724,726 $1,093,967,390 +$44,483,048 $9.88 164
2016 Q3 106,009,210 $1,279,976,335 +$17,256,778 $12.08 161
2016 Q2 104,978,572 $906,530,216 +$19,234,625 $8.63 159
2016 Q1 102,642,856 $973,879,684 +$1,362,632 $9.47 159
2015 Q4 98,841,329 $1,712,905,548 +$8,221,079 $17.33 164
2015 Q3 98,182,404 $1,318,661,570 +$3,328,652 $13.43 174
2015 Q2 97,583,561 $2,203,565,952 +$80,075,442 $22.58 158
2015 Q1 94,411,049 $1,348,555,169 +$51,544,544 $14.28 137
2014 Q4 91,157,821 $879,597,787 +$20,012,260 $9.65 130
2014 Q3 88,971,177 $809,677,785 +$28,690,375 $9.1 118
2014 Q2 85,679,010 $846,469,840 -$18,616,849 $9.88 127
2014 Q1 85,850,619 $1,090,677,475 +$78,418,989 $12.7 129